SCYX 1.18 (+0%)
US8112922005Drug ManufacturersDrug Manufacturers - Specialty & Generic

SCYNEXIS (SCYX) Stock Highlights

1.18 | +0%
2024-11-21 06:12:50
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Statistics

Range Today
1.15 1.19
Volume Today 108.3K
Range 1 Year
1.15 3.07
Volume 1 Year 48.68M
Range 3 Year
1.15 8.1
Volume 3 Year 272.83M
Range 10 Year
1.15 150
Volume 10 Year 457.48M

Highlights

Market Capitalization 49.71M (micro)
Floating Shares 37.56M
Current Price 1.18
Price To Earnings -1.76
Price To Revenue -0.38
Price To Book 0.85
Earnings Per Share -0.75
Payout Ratio 0%

Performance

Latest 0%
1 Month -25.32%
3 Months -30.59%
6 Months -58.01%
1 Year -27.16%
3 Years -84.51%
5 Years -89.27%
10 Years -98.74%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.